EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect

Conghua Lu, Ziyuan Gao, Di Wu, Jie Zheng, Chen Hu, Daijuan Huang, Chao He, Yihui Liu, Caiyu Lin, Tao Peng, Yuanyao Dou, Yimin Zhang und 5 weitere

Journal for ImmunoTherapy of Cancer · 2024-06 · 12 (6) · e009165

DOI: 10.1136/jitc-2024-009165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 21.06.2024. Verfasst von Conghua Lu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Protein Kinase Inhibitors, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chongqing Technology Innovation and Application Development Special Key Project, Chongqing Science and Technology Commission, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The dynamic interplay between tyrosine kinase inhibitors (TKIs) and the tumor immune microenvironment (TME) plays a crucial role in the therapeutic trajectory of non-small cell lung cancer (NSCLC). Understanding the functional dynamics and resistance mechanisms of TKIs is essential for advancing the treatment of NSCLC.

Methods

This study assessed the effects of short-term and long-term TKI treatments on the TME in NSCLC, particularly targeting epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations. We analyzed changes in immune cell composition, cytokine profiles, and key proteins involved in immune evasion, such as laminin subunit γ−2 (LAMC2). We also explored the use of aspirin as an adjunct therapy to modulate the TME and counteract TKI resistance.

Results

Short-term TKI treatment enhanced T cell-mediated tumor clearance, reduced immunosuppressive M2 macrophage infiltration, and downregulated LAMC2 expression. Conversely, long-term TKI treatment fostered an immunosuppressive TME, contributing to drug resistance and promoting immune escape. Differential responses were observed among various oncogenic mutations, with ALK-targeted therapies eliciting a stronger antitumor immune response compared with EGFR-targeted therapies. Notably, we found that aspirin has potential in overcoming TKI resistance by modulating the TME and enhancing T cell-mediated tumor clearance.

Conclusions

These findings offer new insights into the dynamics of TKI-induced changes in the TME, improving our understanding of NSCLC challenges. The study underscores the critical role of the TME in TKI resistance and suggests that adjunct therapies, like aspirin, may provide new strategies to enhance TKI efficacy and overcome resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentProtein Kinase InhibitorsLung NeoplasmsCarcinoma, Non-Small-Cell LungHumansAnimalsMiceDrug Resistance, NeoplasmFemaleErbB ReceptorsCell Line, TumorMutation

Stichwörter der Autor:innen

ImmunosuppressionLung CancerTumor microenvironment - TME

Substanzen

Protein Kinase InhibitorsErbB Receptors

Autor:innen und Institutionen

  • Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
  • Chongqing Key Laboratory of Precision Medicine and Prevention of Major Respiratory Diseases, Chongqing, China.
  • School of Medicine, Chongqing University, Chongqing, China.
  • Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, China.
  • Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China heyong@tmmu.edu.cn hanrui0018@163.com.

ORCID-Profile: Yong He

Förderung

  • Chongqing Technology Innovation and Application Development Special Key Project
  • Chongqing Science and Technology Commission
  • National Natural Science Foundation of China
  • Clinical Medical Technology Innovation Ability Training Program
  • Chongqing Graduate Scientific Research Innovation Project

Zitieren

APA

Lu, C., Gao, Z., Wu, D., Zheng, J., Hu, C., Huang, D., He, C., Liu, Y., Lin, C., Peng, T., Dou, Y., Zhang, Y., Sun, F., Jiang, W., Yin, G., Han, R., & He, Y. (2024). Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect. Journal for ImmunoTherapy of Cancer, 12(6), e009165. https://doi.org/10.1136/jitc-2024-009165

Vancouver

Lu C, Gao Z, Wu D, Zheng J, Hu C, Huang D, et al. Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect. Journal for ImmunoTherapy of Cancer. 2024;12(6):e009165. doi:10.1136/jitc-2024-009165

BibTeX
@article{Lu2024,
  author = {Lu, Conghua and Gao, Ziyuan and Wu, Di and Zheng, Jie and Hu, Chen and Huang, Daijuan and He, Chao and Liu, Yihui and Lin, Caiyu and Peng, Tao and Dou, Yuanyao and Zhang, Yimin and Sun, Fenfen and Jiang, Weiling and Yin, Guoqing and Han, Rui and He, Yong},
  title = {Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {6},
  pages = {e009165},
  doi = {10.1136/jitc-2024-009165}
}
Kostenlos starten →